Immunocore ’s Lead Asset Tebentafusp Gains Fast Track Designation for Metastatic Uveal Melanoma
OXFORD, England& CONSHOHOCKEN, Pa.--April 03, 2019 --Immunocore Limited, a leading T Cell Receptor (TCR) biotechnology company, today announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Biotechnology | Clinical Trials | Eye Cancers | Food and Drug Administration (FDA) | Melanoma | Pharmaceuticals | Skin Cancer | Uveal Melanoma